Monsanto Technology LLC

University of Illinois

Justin Robert Struble

Stephen J Davis

Kaitlyn C Gray

Martin D Burke

Stephen Scott Davis

David M Knapp

Ian Dailey

Brice E Uno

Pulin Wang

Nagarjuna Palyam

Terri L Boehm

Daniel Patrick Walker

Jeffery N Carroll

G Davis Harris, Jr

Eduardo Aurelio Casanova

Matthew D McReynolds

Jian Xu

Mangesh Bore

Peng Fan

Matthew D Mcreynolds

Jr G Davis Harris

The present invention is generally directed to improved processes for the preparation of various phosphorus oxides and phosphoric acid. Phosphorus oxides prepared in accordance with the present invention include phosphorus (III) oxides (e.g., tetraphosphorus hexaoxide (PO)). Phosphorus (III) oxides such as POare useful products and are also useful as precursors in preparation of other products, including phosphorous acid (HPO) and other phosphorus-containing chemicals. Certain aspects of this invention are also directed to using various byproducts formed during POproduction as precursors for the formation of phosphoric acid (HPO) and PO. In particular, the present invention is directed to improved processes for the preparation of phosphorus (III) oxides (e.g., PO) suitable for use in the preparation of phospho-herbicides such N-(phosphonomethyl)glycine (glyphosate) and precursors thereof (e.g., N-(phosphonomethyl)iminodiacetic acid (PMIDA)). The present invention is thus further directed to preparation of these compounds.

Phosphorus oxide and phosphoric acid production processes

This invention relates to an improved electrodialysis method for preparing an amino acid from a salt of the amino acid utilizing a three-compartment bipolar membrane electrodialysis process wherein an aqueous electrolyte comprising an exogenous acid is added to the acid compartment of a three-compartment bipolar membrane apparatus. The exogenous acid is different than the amino acid and typically has a pKa less than the pKa of the amino acid.

Three-compartment bipolar membrane electrodialysis of salts of amino acids

Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3′ or C4′ modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Amphotericin B derivatives with improved therapeutic index

Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3' or C4&#x2032; modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

The present disclosure relates, in general, to 5-halo-3,6-dichlorosalicylic acid compounds, 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 5-halo-3,6-dichlorosalicylic acid compounds, processes for preparing 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 3,6-dichlorosalicylic acid compounds, and processes that employ such compounds as intermediates in the preparation of the herbicide dicamba.

3,6-dichlorosalicylic acid compounds and related synthetic processes

Growing community of inventors

Ballwin, MO, United States of America

Justin Robert Struble